Documented formulation program · 01
SulfoGenz Minoxidil-Sulfate Emulsion: V1 to V3
A cross-border formulation program that moved a minoxidil-sulfate emulsion from an early Brazilian pharmacy build through documented user feedback, vehicle redesign, controlled production procedures, and a China-side V3 pilot.
- Organizations
- FolliGenz Therapeutics Corporation, Biotica Consulting LLC, Farmácia Manipula, and Nanjing Hemu Haohai Biotechnology Co., Ltd.
- Project period
- 2025 to 2026
- Prepared by
- Biotica Consulting LLC
- Last reviewed
- July 31, 2026
- Status
- V3 pilot sampling and validation planning
- Format
- Formulation research, pharmacy collaboration, and technical transfer
Biotica Consulting supported the research, formulation architecture, documentation, and partner handoff described here. Collaboration history, sensory observations, accelerated screening, and international fulfillment statements are attributed to records supplied by the project team unless a public source is linked. Confidential recipes, quantities, process settings, and operating sequences are intentionally not published.
The formulation had to become manufacturable before it could be studied
Before CTI mapped skin penetration, the formulation itself had to be made buildable. FolliGenz Therapeutics, with research and development support from Biotica Consulting, worked with Farmácia Manipula in Espírito Santo, Brazil, to translate SulfoGenz into a manufactured 10% minoxidil-sulfate emulsion. CTI's later report identifies Manipula as the manufacturer of the September 2025 sample, creating a documented line from Brazilian formulation work to live-human analytical testing.
V1 established the first manufactured emulsion and generated useful failure data. FolliGenz's public feedback record documented visible grains and a dispenser opening that was too small for the product. The page identified the stearic and shea-derived lipid system as the likely source rather than minoxidil sulfate itself. Internal batch review later identified the solid shea-butter glyceride load as a cause of waxy clumping and separation. FolliGenz and Biotica used those observations to revise the vehicle, dispensing approach, and production controls.
According to the project team, Manipula was the first program partner to conduct accelerated heat or oven screening. That work informed an 8 to 12 month working shelf-life estimate when the V1 product was stored under the version-specific label conditions of 20 to 25 °C, or 68 to 77 °F. The CTI Raman report later listed a one-year shelf life in customer-provided sample metadata. That entry is not the result of a CTI stability study, and the underlying Manipula screening protocol is not reproduced here.
V2 moved the target toward a watery, milky serum that spreads quickly, dries fast, and avoids a sticky finish. The internal production framework reduced the waxy load, tightened phase and temperature control, used controlled sonication, and formalized preservation, pH, filling, batch coding, and packaging checks. The confidential operating recipe remains private, but the public record can show the diligence behind the redesign.
V3 carried the work into a China-side pilot with Nanjing Hemu Haohai Biotechnology, also known as Hemuchem. The team adapted the earlier low-ethanol lotion-serum architecture by replacing Aminexil with minoxidil sulfate, reducing the water phase, and proposing a 5% to 7% active range. Project correspondence records a 5% pilot preference and sample preparation. Team evaluation described a smoother liquid-lotion feel with no visible residue. Those are prototype observations, not blinded consumer-study results.
FolliGenz reports that additional Brazilian compounding partners later supported manufacturing and international fulfillment from Brazil. This is presented as client-reported operating history. Manipula's public website documents delivery throughout Brazil, not worldwide shipping. Every destination market still requires its own product-classification, labeling, import, fulfillment, and claims review.
A formulation program that reached packaged production
From production footage to the V3 presentation
The roll begins with project footage, then moves through physical packaging details and the later 5% and 10% visualization. Select any image to inspect the full WebP asset.
Packaging-line project footage
A six-second portrait clip from the SulfoGenz packaging record, preserved as a browser-ready MP4.
V1 package front
The earlier 10% presentation documented the stabilized lipid-matrix positioning used during the Brazilian program.
Label and storage details
The photographed label records version-specific storage at 20 to 25 °C, or 68 to 77 °F. That range is not generalized to every later formulation.
Box and printed insert
The packaging system paired the primary carton with use, handling, and safety information for the shipped product.
Later product visualization
A transparent-background rendering used to explore the 5% and 10% product family and its updated visual system.
Defined work across four organizations
FolliGenz Therapeutics Corporation
Set the product brief, collected user feedback, directed V1 to V3 iteration, evaluated prototypes, and coordinated commercialization and international fulfillment partners.
Biotica Consulting LLC
Connected literature review, excipient rationale, failure analysis, process documentation, partner communication, validation questions, and market-readiness considerations.
Farmácia Manipula
Produced the documented V1 emulsion, supported early packaging and fulfillment, and, according to the project team, performed the first accelerated heat or oven screening for the program.
Nanjing Hemu Haohai Biotechnology Co., Ltd.
Coordinated OEM feasibility, sample preparation, and testing discussions for the V3 pilot built around a proposed 5% to 7% minoxidil-sulfate range.
A feedback-led formulation path
- 01
First manufactured 10% emulsion
FolliGenz, Biotica, and Manipula translated the concept into a packaged Brazilian pharmacy build that could support initial international fulfillment and later analytical testing.
- 02
Grains and dispensing became design inputs
Public feedback and internal batch review connected the physical issue to the waxy stearic and shea-derived system. The team treated the complaint as formulation evidence, not a customer workaround alone.
- 03
Lighter feel and tighter controls
The next version targeted a watery, milky, fast-drying and non-sticky serum while formalizing material, process, QC, filling, coding, and packaging controls.
- 04
A smoother 5% to 7% platform adaptation
FolliGenz and Hemu Haohai moved the reduced-water architecture into pilot sample work, with a 5% preference recorded during OEM feasibility discussions.
- 05
Formulation and penetration records remain separate
The CTI Raman study added live-human penetration evidence for one submitted V1 sample. It did not test shelf life, long-term safety, scalp targeting, or comparative product performance.
A controlled workflow and the documents around it
The V3 production cookbook records development across four internal batches and a target that is watery, milky, fast-drying, and physically uniform. The supporting equipment SOP covers the packaging line and QC bench used to make batch decisions repeatable.
The public summary intentionally stops at the control framework. It does not reveal ingredient quantities, processing temperatures, timing, equipment settings, exact order of addition, or proprietary troubleshooting thresholds.
A separate two-page municipal environmental license documents the Brazilian compounding site. It is included as operating-context evidence and is not relabeled as an ANVISA GMP certificate.
SulfoGenz V3 production cookbook
Documents controlled aqueous and lipid phases, water quality, heat-managed homogenization, preservation, diluted-sample pH checks, filling verification, and lessons logged across four batches.
Equipment operation SOP framework
Defines calibration, monitoring, in-process fill checks, coding, and package-finishing controls for the production environment. It is a control framework, not a stability result.
Manipula municipal environmental license
Issued by the Municipality of Cariacica through its city-development and environmental secretariat, LAC 26/2021 authorizes Manipula Farmácia de Manipulação Ltda. to conduct pharmacy compounding at the listed Cariacica site. It states a 3,650-day validity period from receipt. The issuing authority and document title identify it as an environmental license, not an ANVISA Certificate of Good Manufacturing Practices.
The conditions page remains part of the authorization
The reverse states that the attached conditions form an integral part of LAC 26/2021 and must be completed within the deadlines established by the environmental authority.
Packaging and presentation archive
The retained images connect formulation decisions to the packaging, storage, handling, and presentation work required for a shippable product.
The internal SOP validates a repeatable development workflow across the recorded batches. The municipal environmental license documents one authorization relevant to the site, but it does not substitute for sanitary licensing, evidence of compliance with Brazilian pharmacy-compounding requirements, or a separately issued ANVISA GMP certificate.
Questions the work was designed to answer
- How could a difficult aqueous minoxidil-sulfate active be placed into a physically usable emulsion?
- What did the V1 grains and dispenser constraint reveal about the lipid and wax system?
- How could V2 improve dry-down, spread, residue, and production repeatability without publishing the proprietary recipe?
- Which parts of the earlier Aminexil lotion-serum architecture could be adapted for a 5% to 7% minoxidil-sulfate V3 pilot?
- Which shelf-life statements come from accelerated screening, package metadata, or direct testing, and how should each be labeled?
- What additional evidence and destination-market review are needed before stronger global product claims?
Formulation progress separated from proof still pending
The Brazilian build created a traceable starting point
The CTI Raman report identifies Manipula as manufacturer of the submitted September 2025 emulsion. Manipula's official history supports describing it as an established Brazilian compounding pharmacy, while the international collaboration and fulfillment history remains attributed to FolliGenz project records.
The supplied Manipula record is an environmental license, not GMP certification
The two-page LAC 26/2021 was issued by the Municipality of Cariacica through its city-development and environmental secretariat. It authorizes Manipula Farmácia de Manipulação Ltda. to conduct pharmacy compounding at the listed site and states a 3,650-day validity period from receipt. It was not issued by ANVISA and should not be described as an ANVISA Certificate of Good Manufacturing Practices. ANVISA defines CBPF as a distinct certificate issued by the agency, while pharmacy-compounding practices are addressed separately under RDC 67/2007.
User feedback directly changed the formulation
FolliGenz publicly documented grains and a restrictive bottle opening. Its page identified stearic acid and shea-derived esters as likely contributors rather than the active. The internal batch record later tied a solid shea-butter glyceride load to waxy clumping, leading to removal and vehicle redesign.
V2 was designed around use quality and reproducibility
The redesign targeted a more liquid, quick-drying, non-sticky feel and documented controls for mixing, heat, preservation, QC, filling, coding, and packaging. These are development and team-observation claims, not blinded consumer results.
V3 adapted a platform instead of merely swapping an active
Project correspondence records a proposed 5% to 7% minoxidil-sulfate range, reduced water, a 5% pilot preference, and sample preparation. The aim was a smoother liquid-lotion feel with no visible residue. Hemu Haohai's public catalog supports its minoxidil-sulphate supply role, not a claim that the Nanjing entity was the finished-product legal manufacturer.
Shelf-life evidence is stated at the level available
The project team attributes an 8 to 12 month V1 working estimate to Manipula's accelerated heat or oven screening under controlled 20 to 25 °C, or 68 to 77 °F, storage. CTI's Raman report lists one year only as submitted sample metadata. Neither item is presented as a CTI stability result for V2 or V3.
A difficult active makes formulation evidence important
Peer-reviewed literature describes aqueous stability and delivery challenges for minoxidil sulfate and evaluates vesicular delivery approaches. Those studies support the technical rationale for structured formulation work, but they do not independently test SulfoGenz.
Global fulfillment and market authorization are different questions
FolliGenz reports that additional Brazilian compounding partners later supported manufacturing and international fulfillment. That operating history does not itself establish product authorization, import eligibility, labeling compliance, or claims permission in every destination market.
Evidence required before stronger shelf-life or market claims
The project record is a development input, not permission to outrun the evidence. These are the next questions for direct testing and review.
- Can Manipula provide its current sanitary operating license, technical-responsibility record, evidence of compliance with RDC 67/2007, and any separately issued ANVISA CBPF if that certification is claimed?
- Can the complete Manipula accelerated-screening protocol, conditions, acceptance criteria, observations, and signed report be archived?
- Can real-time and accelerated stability confirm assay, impurities, appearance, phase behavior, pH, viscosity, packaging compatibility, and microbial quality for each final version?
- Can particle size, distribution, morphology, encapsulation, and release data substantiate any specific liposomal or delivery-system claim?
- Can Hemu Haohai identify the finished-product manufacturing entity, facility qualifications, batch records, release tests, and change-control responsibilities?
- Can blinded sensory or consumer testing reproduce the quick-drying, non-sticky, smooth, and residue-free observations?
- Can preservative challenge, microbiological, scalp-tolerability, and repeat-use studies support the intended use conditions?
- What classification, claims, registration, import, labeling, and fulfillment rules apply in each intended destination market?
- Can the CTI Raman result be reproduced with a vehicle control, comparator, larger sample, and scalp-relevant study design?
Progress stated at the level the work supports
SulfoGenz is a formulation-development story built from iteration, not a single successful first batch. FolliGenz, Biotica, and Manipula converted a difficult minoxidil-sulfate concept into a packaged Brazilian V1, captured the grains and dispensing constraint, and used that evidence to make V2 lighter, quicker-drying, and more controllable. The V3 Hemu Haohai pilot adapted the platform toward a proposed 5% to 7% range with reduced water and a smoother, residue-free target. The record shows meaningful formulation and production diligence while keeping stability, sensory, penetration, regulatory, and market-access claims within the evidence actually available.
FolliGenz and Hemu Haohai connected the product brief to manufacturing execution
Biotica supported research translation, formulation decisions, technical handoffs, and validation planning across the product and manufacturing teams.
Project records and public sources
Private records document the collaboration and process history. Public partner pages and peer-reviewed literature provide context, not independent verification of every project outcome. Confidential formulation parameters are intentionally excluded.
- 01Private project record
SulfoGenz V1 to V3 development and fulfillment record
FolliGenz Therapeutics Corporation and Biotica Consulting LLC · Project correspondence and operating history · 2025 to 2026
- 02Confidential project record
SulfoGenz Production Cookbook · Version 3 Final
FolliGenz Therapeutics Corporation · Confidential production SOP · batches 001 to 004
- 03Private project record
Equipment Operation SOPs · Packaging Line and QC Bench
FolliGenz Therapeutics Corporation · Internal control framework · version 1.2
- 04Project-supplied public-authority record
Licença Ambiental por Adesão e Compromisso · LAC 26/2021
Prefeitura Municipal de Cariacica · SEMDEC · Municipal environmental license · issued February 4, 2021
- 05View source
Certificado de Boas Práticas de Fabricação · CBPF
Agência Nacional de Vigilância Sanitária · ANVISA · Official certificate definition
- 06View source
Boas Práticas Farmacêuticas · RDC 67/2007
Agência Nacional de Vigilância Sanitária · ANVISA · Official pharmacy-compounding guidance
- 07Private project record
Manipula accelerated heat or oven screening summary
FolliGenz project team · Client-reported project history · underlying dataset not reproduced
- 08Private project record
Hemu Haohai V3 pilot correspondence and sample record
FolliGenz Therapeutics Corporation and Nanjing Hemu Haohai Biotechnology Co., Ltd. · Private formulation-development correspondence
- 09Private project record
SulfoGenz packaging, production video, and rendering archive
FolliGenz Therapeutics Corporation · Project media record
- 10Private project record
CTI Test Report · MINOXIDIL-SULFATE 10% · Sample HBS00029001
Centre Testing International Group Co., Ltd. · Entrusted-testing report · 14 pages · 2026
- 11View source
Nossa Historia
Farmácia Manipula · Official company page
- 12View source
FolliGenz User Feedback No. 1 · Grains and Small Bottle Hole
FolliGenz Therapeutics Corporation · Official public feedback record
- 13View source
SulfoGenz 5% Liposomal Minoxidil Sulfate
FolliGenz Therapeutics Corporation · Official product page
- 14View source
Minoxidil Sulphate product details
Nanjing Hemu Haohai Biotechnology Co., Ltd. · Official product page
- 15View source
Minoxidil sulfate liposomes for enhanced dermal delivery
PubMed · Peer-reviewed formulation and ex-vivo delivery study
- 16View source
Use of minoxidil sulfate versus minoxidil base in androgenetic alopecia treatment
PubMed Central · Peer-reviewed clinical and formulation context review
Project evidence and literature must be read within their stated methods and limitations. This page is not medical, clinical, regulatory, or legal advice.
Related projects and research
Follow adjacent formulation, partner, supplier, and research questions while keeping each evidence type clearly labeled.
Need a difficult formulation moved from rationale to manufacturing handoff?
Biotica connects literature review, formulation architecture, user-feedback analysis, partner coordination, production documentation, market analysis, and validation planning around the decision your program needs to make.
Discuss a formulation program